PRINCETON, N.J., April 7, 2020 /3BL Media/ -Bristol Myers Squibb (NYSE: BMY) today announced an expansion of its existing patient support programs to help eligible unemployed patients in the U.S. who have lost their health insurance due to the COVID-19 pandemic.
The expanded program offers access to any branded Bristol Myers Squibb medicine for free, including some of its most widely prescribed products, as well as those prescribed via telehealth services. The program features:
When the news of the coronavirus first emerged, Gilead immediately began to investigate the potential of remdesivir, a medicine we had been studying for many years as part of our extensive research in antivirals. Remdesivir had never been approved for use but based on what we had learned to date, we knew it might have potential with the novel coronavirus. Since then, we have been working with the greatest sense of urgency and responsibility to determine whether remdesivir does indeed work against COVID-19.
KENILWORTH, N.J., September 13, 2019 /3BL Media/ -- The Merck Foundation (the Foundation) has launched HIV Care Connect, a $7 million, five-year initiative to help reduce disparities in access to care and improve health outcomes for persons with HIV living in vulnerable and underserved Southeastern U.S. communities.
Medical Technology Transfer and Services to bring low-cost access to neonatal treatment to 10 African countries
HANOI, Vietnam, March 6, 2019 /3BL Media/ – Medical devices designer and manufacturer Medical Technology Transfer and Services (MTTS) has answered the Business Call to Action (BCtA), as the social enterprise commits to delivering access to neonatal treatment for 495,000 low income patients in 10 African countries through the delivery of devices to 200 hospitals. MTTS aims to meet their goal by 2022.
For Darcy Doege, R.N., B.S.N., of the Levine Cancer Institute, finding cancer early in patients means hitting the road.
Darcy is the Program Coordinator for the Lung B.A.S.E.S. 4 Life Program for the Charlotte-based cancer center, which launched the first mobile lung screening unit in the U.S. in 2017. This innovative idea was built to increase the early detection of lung cancer for underserved populations across North and South Carolina, thanks to a grant from the Bristol-Myers Squibb Foundation
2018 Challenge Will Award a Total of $100,000 in New Grants to Help Reduce the Unequal Burden of Cancer - All Healthcare Innovators Encouraged to Apply
TOKYO, June 1, 2018 /3BL Media/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") have announced the launch of the third annual Astellas Oncology C3 Prize (Changing Cancer Care), a global challenge aimed at inspiring non-treatment ideas that may improve cancer care for patients and their loved ones. This year's challenge will focus on solutions for cancer care in low- and middle-income countries, which bear a disproportionate burden of the global cancer epidemic.1,2,3